Endpoints News· @endpts · X·· 12 天前AI 评分42
AI 导读
牛津大学衍生公司 Alethio 融资 9000 万美元,用于推进其治疗一种罕见血癌的抗体药物,此时距其结束隐身模式约一年。 https://endpoints.news/alethio-clinches-90m-to-advance-antibody-for-essential-thrombocythemia/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
正文
Oxford spinout Alethio raised $90M to advance its antibody for a rare blood cancer, about a year after emerging from stealth. https://endpoints.news/alethio-clinches-90m-to-advance-antibody-for-essential-thrombocythemia/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com